Skip to main content

Table 1 Baseline and demographic variables of patients

From: Comparison of therapeutic effects of N-Acetylcysteine with pregabalin in improving the clinical symptoms of painful diabetic neuropathy: a randomized, double-blind clinical trial

Variable

Pregabalin

N-acetylcysteine

P-value

Gender

 Male (%)

7 (13.7%)

9 (17.6%)

0.59

 Female (%)

44 (86.3%)

42 (82.4%)

Average age (year)

57 ± 9

55± 8

0.22

Average duration of diabetes (years)

7.75±5.5

4.8±8.25

0.65

Average duration of neuropathy (months)

19.9±19.8

20±13

0.97

Urea level (mg / dL)

22.0±11.3

22±7

0.87

Creatinine (mg / dL)

1.0±0.16

1.0±0.2

0.36

Hemoglobin A1C (%)

7.9±0.8

8±0.8

0.54

Triglyceride (mg / dL)

171.7±85.5

158.2±71.2

0.39

LDL (mg / dL)

100.8±27.2

87±22

0.004

HDL (mg / dL)

43±10

42.5±7.6

0.81